within Pharmacolibrary.Drugs.ATC.N;

model N04AA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.33,
    Cl             = 0.0005166666666666667,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.024,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0085,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04AA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Biperiden is an anticholinergic drug primarily used for the treatment of Parkinson's disease and drug-induced extrapyramidal symptoms. It acts as a muscarinic acetylcholine receptor antagonist, helping to restore the balance between dopamine and acetylcholine in the central nervous system. Biperiden is still approved and in use for certain cases of parkinsonism and dystonia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>von Bahr, C, et al., &amp; Widman, M (1990). Clinical pharmacokinetics of remoxipride. <i>Acta psychiatrica Scandinavica. Supplementum</i> 358 41–44. DOI:<a href=\"https://doi.org/10.1111/j.1600-0447.1990.tb05284.x\">10.1111/j.1600-0447.1990.tb05284.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1978486/\">https://pubmed.ncbi.nlm.nih.gov/1978486</a></p></li><li><p>Hollmann, M, et al., &amp; Wetzelsberger, N (1984). Biperiden effects and plasma levels in volunteers. <i>European journal of clinical pharmacology</i> 27(5) 619–621. DOI:<a href=\"https://doi.org/10.1007/BF00556903\">10.1007/BF00556903</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6519170/\">https://pubmed.ncbi.nlm.nih.gov/6519170</a></p></li><li><p>Hollmann, M, et al., &amp; Crema, A (1987). Pharmacokinetic-dynamic study on different oral biperiden formulations in volunteers. <i>Pharmacopsychiatry</i> 20(2) 72–77. DOI:<a href=\"https://doi.org/10.1055/s-2007-1017079\">10.1055/s-2007-1017079</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3588663/\">https://pubmed.ncbi.nlm.nih.gov/3588663</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04AA02;
